SCREENING FOR CHRONIC KIDNEY DISEASE IN ADULT MALES IN VOJVODINA: A CROSS-SECTIONAL STUDY

Velibor Ćabarkapa¹,², Branislava Ilinčić¹,², Mirjana Đerić¹,², Isidora Radosavkić², Mirko Šipovac³, Jan Sudji³, Veljko Petrović⁴

¹Department of Pathophysiology and Laboratory Medicine, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
²Center for Laboratory Medicine, Clinical Center of Vojvodina, Novi Sad, Serbia
³Institute of Occupational Health, Novi Sad, Serbia
⁴Department of Computing and Control Engineering, Faculty of Technical Sciences, University of Novi Sad, Novi Sad, Serbia

Summary

Background: Chronic kidney disease (CKD) is one of the most significant global health problems accompanied by numerous complications, with constant increase in the number of affected people. This number is much higher in early phases of disease and patients are mostly asymptomatic, so early detection of CKD is crucial. The aim was examination of the prevalence of CKD in the general population of males in Vojvodina, based on estimated glomerular filtration rate (eGFR) and urine albumin/creatinine ratio (ACR), and exploring the determinants and awareness of CKD.

Methods: This cross-sectional study included 3060 male examinees from the general population, over 18 years of age, whose eGFR and ACR were calculated, first morning urine specimen examined, arterial blood pressure measured and body mass index calculated. Standard biochemistry methods determined creatinine, urea, uric acid and glucose serum concentrations as well as albumin and creatinine urine levels.

Results: Prevalence of CKD in the adult male population is 7.9%, highest in men over 65 years of age (46.7%), while in the other age groups it is 3.6–12.6%. The largest number of examinees with a positive CKD marker suffer from arterial hypertension.

Address for correspondence:
Velibor Ćabarkapa
Department of Pathophysiology and Laboratory Medicine, Faculty of Medicine, University of Novi Sad
Hajduk Veljkova 3, 21000 Novi Sad, Serbia
Phone: +38121-484-3475
Fax: +38121-529-148
e-mail: velibor.cabarkapa@mf.uns.ac.rs

List of abbreviations: CKD – chronic kidney disease; ACR – albumin/creatinine ratio in urine; eGFR – estimated glomerular filtration rate; CVD – cardiovascular disease; ESRD – end stage renal disease; DM – diabetes mellitus; HTA – arterial hypertension; BMI – body mass index; FBG – fasting blood glucose; SBP – systolic blood pressure; DBP – diastolic blood pressure.
hypertension (HTA) and diabetes mellitus (DM). Only 1.3% of examinees with eGFR < 60 ml/min/1.73 m² and/or ACR ≥ 3 mg/mmol had been aware of positive CKD biomarkers.

**Conclusions:** Obtained results show the prevalence of CKD in adult males is 7.9%, HTA and DM are the most important CKD risk factors and the level of CKD awareness is extremely low (1.3%) indicating the necessity for introduction of early stage disease recognition measures, including raising CKD awareness.

**Keywords:** chronic kidney disease, prevalence, risk factors, screening

---

**Introduction**

Chronic kidney disease (CKD) is defined as abnormality of kidney structure or function, present for ≥ 3 months with implications for health (1). Abnormalities of kidney structure or function include: pathological findings in urine sediment (erythrocyturia, leukocyturia, cylindruria), pathological albuminuria (≥ 30 mg/24 h or urinary albumin-creatinine ratio (ACR) ≥ 3 mg/mMol), electrolytic disbalance and other abnormalities caused by tubular defects, histopathological damages, structural damages detected by visual inspection, history of kidney transplantation and/or glomerulus filtration rate (GFR) < 60 ml/min/1.73 m². Chronic kidney disease is divided into 5 stages based on the GFR level and albuminuria or ACR (1).

Number of CKD patients is constantly increasing and epidemiologic data is mostly related to late stages of the disease (2). Although the number of patients treated by the renal replacement modality exceeds 2 million, it is thought that the number of patients in the early CKD stages (first three stages) is more than ten times larger (3, 4). One of the main problems in the detection of these patients is the lack of symptoms (5). Aside from its high prevalence and long asymptomatic course, CKD is relevant since it is accompanied by very high cardiovascular comorbidity and mortality (6). More than 50% of CKD patients die from cardiovascular diseases (CVD) before the beginning of treatment with one of the methods for renal function replacement, that is, the risk of CVD in these patients is higher than the risk of progression to end-stage renal disease (ESRD) (7).

According to the 2016 European Guidelines on CVD prevention, individuals with moderate CKD (GFR 30–59 mL/min/1.73 m²) and severe CKD (GFR <30 mL/min/1.73 m²) are high-risk and very high-risk categories, respectively (8). Individuals at highest risk gain most from preventive efforts. Consequently, it is clear that early CKD detection is of utmost importance and one of the ways to achieve it is by using suitable laboratory tests.

Among the most common causes of CKD and progression to ESRD are diabetes mellitus (DM) (33% of adult CKD cases) and arterial hypertension (HTA) (21% of adult CKD cases) (9, 10). The reason is a constant rise in the number of these patients which is «a medical catastrophe of world-wide dimensions» (11).

**Prevalence of CKD in Europe is from 3.3% in Norway up to 17.5% in North Germany, 8.9% in Brazil, 12.9% in Japan, 13.1% in North America, 16% in Australia and 17.2% in India (12–17). For the population on the territory of Serbia data is scarce and mostly related to reports on the number of patients treated by one of the renal replacement modalities. The only published study on CKD screening was done in 2012 on HTA and DM patients, as well as patients over 60 years of age (18). However, as far as we know, studies on the prevalence of CKD in the general population on the territory of Serbia have never been published. The aim of this study is to examine the prevalence of CKD in the general population of adult males in Vojvodina–Northern Serbia, based on eGFR (mL/min/1.73 m²) and ACR (mg/mMol), and to explore the determinants and awareness of CKD.

**Material and Methods**

**Study group**

This cross-sectional study included 3060 male examinees from the general population, over 18 years of age, from the Vojvodina–Northern Serbia region, who undertook a physical examination at The Workers Health Care Center in Novi Sad in the period from January to June 2015. The study was conducted according to the principles of the Helsinki Declaration and approved by the Ethics Committee of The Workers Health Care Center. Informed consent for participating in the study was obtained from all participants prior to inclusion in the study.

All the examinees filled in a questionnaire consisting of personal and family health history (kidney diseases, HTA, DM, CVD (myocardial infarction, stroke)), and lifestyle (smoking). All the examinees were examined by a doctor, specialist in occupational medicine, and their medical records were used as required by the study. Furthermore, as required by the study, only current smokers were defined as smokers.
and everyone else was defined as non-smokers. Additionally, for the calculation of body mass index (BMI (kg/m²)) the examinees’ height and mass were measured. Depending on their BMI, the examinees were put into three categories: normal-weight (BMI<25 kg/m²), overweight (25≤BMI<30 kg/m²) and obese (BMI>30 kg/m²). All the examinees had their blood pressure measured with the Riva Rocci method, three times on the left arm in a sitting position, and the measure of central tendency of the last two measurements was used for defining the final value of systolic and diastolic blood pressure (SBP and DBP) (19).

Hypertension was defined based on prior diagnosis, that is, the use of antihypertensive therapy, and the examinees with SBP≥140 mmHg and/or DBP≥90 mmHg were assigned to survey high blood pressure category. The examinees with prior diagnosis of DM, that is, the examinees using hypoglycemic therapy were assigned to diabetes patients category and the examinees with fasting blood glucose (FBG) ≥7 mmol/L to survey DM category. The examinees with acute inflammation diseases or malignity were not included in the study.

**Laboratory parameters**

All the examinees had their urine and blood analyzed. Blood and urine samples were analyzed on the same day, immediately after sampling. First voided urine testing was performed by one experienced laboratory technician. The chemical analysis (proteinuria, glycosuria, hematuria) with Acon commercial test strips (Acon Laboratories Inc., USA) was performed, as well as microscopic examination of urine sediment (leukocyturia, erythrocyturia, cylindruria). Proteinuria, hematuria, and glycosuria were defined when dipstick analysis quantified them as 1+ or more, leukocyturia when 8+ or more leukocytes were present per high-power field, erythrocyturia when 3+ or more erythrocytes were present per high-power field and cylindruria when there was a presence of casts in urine sediment. The same urine sample was used for determining albumin level (immunoturbidimetric method on a biochemistry analyzer ADVIA 1800 commercial systems Siemens Healthcare Diagnostics Inc., Germany) and creatinine (Jaffe’s kinetic method). ACR (mg/mmol) was calculated from the received values. The examinees with ACR greater than 3 mg/mmol were defined as having albuminuria (1), and those with the value of ACR greater than 30 mg/mmol were defined as having severe albuminuria. The same biochemistry analyzer was used to determine serum creatinine level with the same method as for urine creatinine, as well as serum glucose concentration with the enzymatic hexokinase method. Estimated glomerular filtration rate (eGFR) (ml/min/1.73 m²) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (20). CKD is defined according to the guideline (1), when there is eGFR<60 ml/min/1.73 m² or when there is eGFR>60 ml/min/1.73 m² and there is a presence of albuminuria > 30 mg/24h or ACR>3 mg/mmol.

**Statistical analysis**

Data was statistically analyzed using statistical software STATISTICA 14 (StatSoft Inc., Tulsa, OK, USA) and is presented graphically and in tabular presentation. Descriptive statistics, including median, arithmetic mean, and standard deviation (SD) were used to describe the studied parameters. Differences in distributions of individual parameters between study groups were analyzed using the parametric Student’s t-test, or the nonparametric Mann-Whitney test in case a distribution showed a significant deviation, while Chi-square test was used for categorical data. Value of p<0.05 was considered statistically significant. Multiple regression analysis was used to form a model for predicting disease indicators.

**Results**

Table I shows some basic characteristics of the examinees. Prevalence of CKD in the adult male population is 7.9%. The percentage of the examinees with CKD increases with older age and it is highest in the examinees over 65 years of age (46.7%), while in other age groups it is between 3.6% and 12.6%. Only 1.3% of the examinees with eGFR<60 ml/min/1.73 m² and/or ACR≥3 mg/mmol were aware of having positive CKD biomarkers.

The prevalence of the examinees with diagnosed HTA is 22.4% and as many as 31.5% of the examinees, who had not been diagnosed with HTA, had elevated SBP and/or DBP during the examination. Sixteen point two percent of the examinees with diagnosed HTA had positive CKD markers (eGFR<60 ml/min/1.73 m² and/or ACR≥3 mg/mmol) as well as 6.5% with survey high blood pressure. The prevalence of the examinees with diagnosed DM is 4.1% and there was 5.1% of the examinees with survey FBG≥7 mmol/L without previous DM diagnosis. Positive CKD markers were present in 22.4% of the examinees with DM and 19.1% of the examinees with survey FBG≥7 mmol/L. Sixty one percent of the examinees with DM also has HTA.

Approximately one-fifth of the examinees (21.4%) are obese and 44% is overweight. Positive CKD markers are present in 9.6% of the examinees with normal weight, 5% of overweight examinees and 9.6% of obese examinees (p>0.05). Percentage of adult males who currently smoke was 40.6%. There was no significant difference in CKD prevalence between smoking and non-smoking (6.7% vs. 8.4%, p>0.05). The examinees with positive CVD history
### Table I Characteristics of participants.

| Participants | N (%) | Mean ± SD | ACR≥3 mg/mmol alone N (%) | eGFR<60 mL/min/1.73 m² alone N (%) | Both N (%) | Total N (%) |
|--------------|-------|-----------|---------------------------|-----------------------------------|------------|-------------|
| Total        | 3060  | (100)     | 180 (5.9)                 | 42 (1.4)                          | 17 (0.6)   | 239 (7.9)   |
| Age (years)  |       |           |                           |                                   |            |             |
| 18–25        | 298 (9.8) | 22.4±2.0 | 17 (5.7)                  | 0                                 | 1 (0.3)    | 18 (6)      |
| 26–35        | 795 (25.9) | 30.6±2.8 | 26 (3.5)                  | 0                                 | 1 (0.1)    | 27 (3.6)    |
| 36–45        | 772 (25.2) | 40.4±2.8 | 34 (4.4)                  | 1 (0.1)                           | 1 (0.1)    | 36 (0.2)    |
| 46–55        | 716 (23.4) | 50.4±2.8 | 52 (7.3)                  | 4 (0.6)                           | 4 (0.6)    | 60 (8.5)    |
| 56–65        | 370 (12.1) | 59.9±3.2 | 52 (8.6)                  | 11 (2.9)                          | 4 (1.1)    | 47 (12.6)   |
| >65          | 109 (3.4)  | 73.0±5.4  | 19 (17.4)                 | 26 (23.8)                         | 6 (5.5)    | 51 (47.7)   |
| Hypertension*|       |           |                           |                                   |            |             |
| Yes, diagnosed | 669 (22.4) | −         | 73 (10.9)                 | 24 (3.6)                          | 11 (1.7)   | 108 (16.2)  |
| Survey high SBP or DBP | 940 (31.5) | −         | 47 (5.0)                  | 12 (1.3)                          | 2 (0.2)    | 61 (6.5)    |
| No           | 1375 (46.1) | −         | 35 (2.5)                  | 4 (0.3)                           | 3 (0.2)    | 42 (3)      |
| DM           |       |           |                           |                                   |            |             |
| Yes, diagnosed | 125 (4.1)  | −         | 25 (20)                   | 2 (1.6)                           | 1 (0.8)    | 28 (31.4)   |
| With hypertension | 75 (60) | −         | 15 (20)                   | 1 (1.3)                           | 1 (1.3)    | 16 (21.6)   |
| Without hypertension | 50 (40) | −         | 10 (20)                   | 1 (2)                             | 0          | 11 (22)     |
| Survey FBG ≥7 mmol/L | 157 (5.1) | −         | 14 (8.9)                  | 13 (8.3)                          | 3 (1.9)    | 30 (19.1)   |
| No           | 2778 (81.8) | −         | 0                         | 0                                 | 0          | 0           |
| BMI (kg/m²)  |       |           |                           |                                   |            |             |
| <25          | 1059 (34.6) | 22.9±1.7 | 64 (6.1)                  | 26 (2.5)                          | 11 (1.0)   | 101 (9.6)   |
| 25–29.99     | 1348 (44.0) | 27.2±1.4 | 57 (4.2)                  | 11 (0.3)                          | 6 (0.5)    | 74 (5)      |
| ≥ 30         | 653 (21.4)  | 33.5±2.6  | 59 (9.0)                  | 5 (0.7)                           | 0          | 64 (9.7)    |
| Current smoking |       |           |                           |                                   |            |             |
| Yes          | 1244 (40.6) | −         | 68 (5.5)                  | 5 (0.4)                           | 10 (0.8)   | 83 (6.7)    |
| No           | 1816 (59.4) | −         | 114 (6.3)                 | 20 (1.1)                          | 19 (1.0)   | 153 (8.4)   |
| Cardiovascular disease |       |           |                           |                                   |            |             |
| Yes          | 25 (0.8)  | −         | 6 (24)                    | 2 (8)                             | 2 (8)      | 10 (40)     |
| No           | 3035 (99.2) | −         | 176 (5.8)                 | 23 (0.8)                          | 15 (0.5)   | 214 (7.1)   |
| Positive family history for |       |           |                           |                                   |            |             |
| Kidney disease | 15 (0.5)  | −         | 2 (13.4)                  | 0 (0)                             | 3 (20)     | 5 (30.4)    |
| Hypertension | 220 (7.2) | −         | 15 (6.8)                  | 4 (1.8)                           | 2 (0.9)    | 21 (9.5)    |
| DM           | 278 (9.1)  | −         | 17 (6.1)                  | 0 (0)                             | 1 (0.5)    | 18 (6.4)    |
| Cardiovascular disease | 251 (8.2) | −         | 2 (0.8)                   | 16 (6.4)                          | 0 (0)      | 18 (7.2)    |

Legend: Cardiovascular disease − stroke or ischemic heart disease, DM − diabetes mellitus, ACR − urine albumin/creatinine ratio, BMI − body mass index, FBG − fasting blood glucose, SBP − systolic blood pressure, DBP − diastolic blood pressure, *without diagnosed DM.
0.8% of the examinees had significantly higher CKD prevalence in comparison with the examinees with negative CVD history (40% vs. 7.3%, p<0.01).

One-third of the examinees with positive family history (PFH) for kidney disease have CKD, that is, 9.5% with PFH for HTA, 6.4% with PFH for DM and 7.2 with PHF for CVD.

In the examinees with eGFR>90 mL/min/1.73 m² and ACR<3 mg/mmol, with no abnormalities detected in first morning urine sample, without diagnosed kidney diseases, HTA, DM, CVD, with negative family history of kidney diseases, the ACR level was (median, lower-upper quartile): 0.44 (0.28–0.77) mg/mmol.

Figure 1 shows the prevalence of pathological findings in chemical (proteinuria) and microscopic...
Figure 3 Urine albumin/creatinine ratio (ACR (mg/mmol)) distribution according to estimated glomerular filtration rate (eGFR (mL/min/1.73 m²)) values in all subjects.

Table II Characteristics of subjects with diabetes mellitus, hypertension, and survey fasting blood glucose level ≥ 7 mmol/L and high systolic (≥140 mmHg) and/or diastolic (≥90 mmHg) blood pressure.

| Subjects                              | Diagnosed DM* | Survey FBG≥7 mmol/L | Diagnosed HTA | Survey high SBP and/or DBP |
|---------------------------------------|---------------|---------------------|---------------|----------------------------|
| Total number (%)                      | 125 (4.1)     | 157 (5.1)           | 669 (21.9)    | 940 (30.7)                 |
| Age (mean ± SD, years)                | 54.6±10.1     | 54.1±12.3           | 51.2±11.1     | 41.3±12.5                  |
| FBG (mean ± SD, mmol/L)               | 9.7±3.3       | 8.3±1.7             | 5.9±1.2       | 5.5±0.9                    |
| BMI (mean ± SD, kg/m²)                | 27.8±4.7      | 27.3±4.5            | 28.4±4.5      | 27.3±3.9                   |
| BMI (kg/m²)                           |               |                     |               |                            |
| <25 (N, %)                            | 45 (36.0)     | 58 (37.1)           | 165 (24.6)    | 268 (28.5)                 |
| 25–29.99 (N, %)                       | 38 (30.4)     | 53 (33.7)           | 276 (41.1)    | 458 (48.7)                 |
| ≥ 30 (N, %)                           | 42 (33.6)     | 46 (29.2)           | 228 (34.3)    | 214 (22.8)                 |
| BP (mean ± SD, mmHg)                  |               |                     |               |                            |
| Systolic                               | 151.6±21.7    | 150.6±21.5          | 156.6±20.1    | 143.3±11.2                 |
| Diastolic                              | 92.2±11.5     | 92.8±11.6           | 98.4±11.6     | 90.7±7.3                   |
| Subjects treated with ACEi (N,%)      | 34.4 (43)     | −                   | 31.4 (210)    | −                          |
| Subjects treated with AT1 receptor antagonist (N,%) | 10.4 (13) | −                   | 11.5 (77)     | −                          |
| Current smokers (N, %)                | 45 (36)       | 50 (31.8)           | 226 (33.9)    | 389 (41.4)                 |
| eGFR (mL/min/1.73 m²) (N,%)            |               |                     |               |                            |
| >90                                   | 52 (41.6)     | 43 (27.4)           | 254 (38.1)    | 556 (59.1)                 |
| 60–89                                  | 70 (56.0)     | 98 (62.4)           | 350 (56.8)    | 370 (39.4)                 |
| <60                                    | 3 (2.4)       | 16 (10.2)           | 34 (5.1)      | 14 (1.5)                   |
| Subjects with (N, %):                 |               |                     |               |                            |
| ACR≥3 mg/mmol                          | 26 (20.8)     | 17 (10.8)           | 84 (12.6)     | 49 (5.2)                   |
| Proteinuria                            | 15 (12.0)     | 16 (11.2)           | 53 (7.9)      | 48 (5.1)                   |
| Glycosuria                             | 31 (24.8)     | 18 (11.5)           | 6 (0.9)       | 10 (1.1)                   |
| Erythrocyturia                         | 27 (21.6)     | 35 (22.3)           | 159 (23.9)    | 176 (18.7)                 |

Legend: *with and without HTA, FBG – fasting blood glucose, BP – blood pressure, BMI – body mass index, ACEI – angiotensin convertase inhibitors, AT1 – angiotensin receptors type 1, ACR – albumin/creatinine ratio, eGFR – estimated glomerular filtration rate.
(erythrocyturia, leukocyturia, cylindruria) examination of first morning urine sample. Erythrocyturia is present in 28% of the examinees, leukocyturia in 9.7%, cylindruria in 0.8% and proteinuria in 5.9%. In the examinees with ACR > 3 mg/mmol, pathological findings of first morning urine sample examination were present in 59.9%.

Figures 2 and 3 show the distribution of the examinees according to the eGFR values, as well as distribution of ACR values according to the eGFR values in all the examinees. Estimated GFR < 60 mL/min/1.73 m² is present in 1.9% of the examinees. ACR ≥ 3 mg/mmol is present in 12.5% of the examinees with eGFR ≥ 60 mL/min/1.73 m². ACR ≥ 3 mg/mmol is present in 40.6% of the examinees with eGFR < 60 mL/min/1.73 m², where half of the examinees have ACR > 30 mg/mmol.

The examinees with positive CKD biomarkers when compared to other examinees had significantly higher serum creatinine concentration (99.0 ± 28.9 μmol/L vs. 89.1 ± 9.1 μmol/L, p < 0.01), urea (6.6 ± 4.95 vs. 5.6 ± 2.2 mmol/L, p < 0.01) and uric acid (290.5 ± 74.7 vs. 268.0 ± 62.2 mmol/L, p < 0.05).

Table II shows the characteristics of subjects with DM, HTA, and survey FBG ≥ 7 mmol/L and high SBP (≥ 140 mmHg) and/or DBP (≥ 90 mmHg). CKD prevalence in the examinees with diagnosed DM is 22.4%, in examinees with survey FBG ≥ 7 mmol/L it is 19.1%, in the examinees with diagnosed HTA 16.7% and in survey high SBP and/or DBP 6.5%. Multiple regression analysis identified age (b = -0.551, p < 0.001) and smoking (b = 0.270, p < 0.001) as the most significant predictors of eGFR.

Discussion

This cross-sectional study of CKD prevalence in the male adult population on the territory of Northern Serbia found CKD presence in 7.9% of the examinees. Only 1.9% of men have eGFR < 60 mL/min/1.73 m², but when ACR ≥ 3 mg/mmol is introduced as a diagnostic criterion, the prevalence increases to 7.9%. Out of the examinees with ACR ≥ 3 mg/mmol, ACR > 50 mg/mmol was present in 20% of the examinees with eGFR < 60 mL/min/1.73 m², in 3.7% of the examinees with eGFR 60–89.9 mL/min/1.73 m² and in 0.8% of the examinees with eGFR ≥ 90 mL/min/1.73 m².

CKD prevalence significantly varies in European countries, from 3.3 to 17.7% and it is higher in the southern than in the northern parts of Europe (14, 19). These variations result from not only increase in the number of DM, HTA and obesity patients, but also from other factors such as nutrition, public health service organization, genetic factors, heterogeneity of laboratory methods, study population heterogeneity, etc. (14). Furthermore, nutrition differences can have a different impact on CKD prevalence, due to its influence on blood creatinine level (protein rich diet), as well as the renal protective or renal damaging effect of certain micros and macronutrients (21, 22). Well-organized public health service can have an important influence on decreased CKD prevalence (23). In applied methodology, there are still inter-laboratory variations, although in most studies the methodology of determining serum creatinine and albumin levels is similar (24).

CKD prevalence varies by gender, where CKD prevalence is higher in women, which could, along with different smoking prevalence, alcohol use, cardiovascular diseases and different hormone metabolism, glomerular hemodynamics, probably be explained by insufficient validity of the estimated GFR formula in the female population (17, 19, 25–28).

Furthermore, CKD prevalence significantly increases with age, and in this study it is significantly higher (p < 0.001) in the over 65 age group (46.7%) in comparison to other groups: it was 3.6–8.5% in 18–55 age group and 12.6% in 56–65 age group. In this and other studies age is a prominent independent risk factor for CKD, in men and women, where people over 65 years of age have significantly higher risk of CKD development compared to those below 65 years of age (19, 25). Specifically, the risk of CKD and albuminuria increases 1.5 times with every 10 years of life, and thus a decrease in GFR with aging cannot be considered as completely normal physiology (18, 29).

There was 21.4% of obese examinees in the general population in this study and 44% of overweight ones. In the European and USA studies the results show similar prevalence of obese (22.3–26.1%) and overweight examinees (31.1–39.4%), while in India the prevalence of obese (11.7%) and overweight (26.4%) examinees is significantly lower in comparison to other countries (13, 15, 25, 27, 29). Although studies state obesity as a CKD risk factor in the general population, specifically in the male population, this study has not shown significant CKD prevalence (9.6 vs. 5 vs. 9.7%, respectively, p > 0.05) between groups of examinees with BMI < 25, 25–29.9, and ≥ 30 kg/m² (19, 25, 30). The results of other studies state higher CKD prevalence among obese (16.6–31.7%) and overweight (31.6–40.0%) examinees in comparison to healthy weight subjects (15, 26, 29). However, for all the stated facts, the study shows that in patients with advanced CKD, higher BMI is combined with small risk of all-cause mortality, which could indicate domination of protective nutrition effect relative to adverse metabolic effects of obesity (30).

Some studies indicate that smoking is associated with development of albuminuria and consequent progression of kidney disease, while other studies did not find association between smoking and decreased GFR or appearance of albuminuria (19, 31, 32). We found that 40.1% of the male population are smok-
ers, which is a significantly higher prevalence than in other studies where it is 13.1–29.1%, and it is higher in the male population than in the female one (19.26–28.32). Although this study indicated smoking as an independent indicator of decreased eGFR, there were no significant differences in CKD prevalence between smokers and nonsmokers (6.7 vs. 8.4%, p>0.05).

Diabetes mellitus and HTA are the most important risk factors for CKD (13, 15, 19, 32). In this study, 21.9% of the examinees had previously diagnosed HTA and another 30.7% survey high SBP or/and DBP, while 4.1% had previously diagnosed DM and another 5.1% survey FBG ≥ 7 mmol/L. CKD prevalence in the examinees with diagnosed DM was 22.4%, in survey FBG ≥ 7 mmol/L examinees 19.1%. In the examinees with diagnosed HTA, CKD prevalence was 16.2%, and in survey high SBP and/or DBP it was 6.5%. This difference in CKD prevalence in the examinees with diagnosed HTA and survey high blood pressure examinees could be explained by the fact that their blood pressure was measured only once, during the examination, which is not enough to make an HTA diagnosis.

Diabetes mellitus and HTA prevalence vary around the world. Diabetes mellitus prevalence in the general population is 6.7−7.4% in Poland, England and the USA, up to 10.8% in Spain and 18.8% in India, and HTA prevalence is 27.1−34.1% in the USA, Poland and England and up to 42.4−43.1% in Spain and India (13, 15, 27, 29). In Serbia, the study by Marinkovic et al. (33) indicated HTA prevalence of 53%, where 20.1% of the examinees had previously diagnosed HTA and another 32.4% of the examinees had survey high SBP and/or DBP. Somewhat higher HTA prevalence was found in female examinees.

In the only published study in Serbia for early detection of CKD in patients with HTA and DM, over 60 years of age, eGFR<60 mL/min/1.73 m² was present in 15−25% of the examinees and microalbuminuria was present in 17−41% of the examinees, depending on the group (18). Another study, in which DM and HTA were independently associated with increased risk of CKD, suggested that CKD prevalence in DM patients is 7.1−41.5% (14, 17, 25, 26, 34, 35), and in HTA patients 12.6−34.5% (13, 14, 17, 19, 26, 29, 34, 36). We found that out of the examinees with CKD, 55% have HTA (43.3%) and DM (11.7%). Studies indicate different HTA and DM prevalence in CKD patients, from surprisingly low 27.7% in Canada, to extremely high 86.3% in Poland (67.8% HTA and 18.5% DM), and 96.1% in India (64.5% HTA and 31.6% DM) and England (74.2% HTA and 21.9% DM) (15, 26, 27, 29).

Zero point eight percent of the examinees in this study had a history of CVD, which is surprisingly low taking into consideration the life habits and type of nutrition in this region and is also lower than indicated in other studies (2.6−6.8%) (17, 25, 34). However, we found that this group of examinees had significantly higher CKD prevalence compared to the group with negative history of CVD (40 vs. 6.9%, p<0.001), which is somewhat higher prevalence than in other studies (21.5–23.9%) (17, 34).

The CKD awareness is one of the significant factors for individual prevention of kidney disease progression and reduction of damaging effects of CKD (37). In this study, only 1.3% of the examinees, with eGFR<60 mL/min/1.73 m² and/or ACR≥3 mg/mmol, had CKD awareness. It is the lowest value in comparison to other studies which state that this percentage is 1.9−22.8% (13, 15, 26, 34). The results of the studies indicate that low level of general education, low income, as well as age, are independently associated with low CKD awareness (38). Considering low CKD awareness level of the examinees in this study, as well as in most other studies, in order to timely recognize and diagnose CKD, it is important not only to raise the awareness level in the general population, but also to educate medical staff at the primary healthcare protection level.

This study had some limitations. Firstly, since this is a cross-sectional study, CKD markers were assessed only once which could have overestimated CKD prevalence in the population of the examinees. Furthermore, the prediction equation formula to estimate GFR calculated from serum creatinine was used. Second, the study included only male examinees. Primarily, it had been planned to include all patients who undertook a physical examination at The Workers Health Care Center in the period from January to June 2015. However, most of the patients were men (88.5%) and due to this gender discrepancy, the results of female population are not presented in this study.

Conclusion

The present paper presents the results of screening for CKD in adult men carried out in Northern Serbia. CKD prevalence is 7.9%, and the awareness of 1.3% is the lowest ever reported. The most important CKD contributing factors in this population are HTA and DM. Considering the obtained results, it can be concluded that it is necessary to introduce measures to raise the awareness level of CKD, particularly among health workers, in order to recognize early stage kidney function impairment which can result in ESRD.

Contribution statement

CV conceived the idea for the study. DjM, CV and IB contributed to the design of the research. All authors were involved in data collection. VP analyzed the data. CV coordinated funding for the project. All authors edited and approved the final version of the manuscript.
Acknowledgments. This work was supported by grant No 114–451–1809/2014 approved by the Provincial Secretariat for Science and Technological Development, Autonomous Province of Vojvodina, Republic of Serbia, and by grant No III46005 approved by the Ministry of Education, Science and Technological Development, Republic of Serbia.

Conflict of interest statement

The authors stated that they have no conflicts of interest regarding the publication of this article.

References

1. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1–136.

2. Paripović A, Stajić N, Putnik J, Bogdanović R. Chronic kidney disease during a 12-year period at tertiary health institution. Srp Arh Celok Lek 2012; 140: 313–20.

3. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089–100.

4. Hallan SJ, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, et al. International Comparison of the Relationship of Chronic Kidney Disease Prevalence and ESRD Risk. J Am Soc Nephrol 2006; 17: 2275–84.

5. Qaseem A, Hopkins R, Sweet D, Starkey M, Shekelle P. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2013; 159: 835–47.

6. Muntner P, He J, Hamm L, Loria C, Welton PK. Renal insufficiency as a predictor of subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 15: 745–53.

7. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629–36.

8. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al.; Authors/Task Force Members. Eur Heart J 2016 May 23. pii: ehw106.

9. Murphree D, Thelen S. Chronic kidney disease in primary care. J Am Board Fam Med 2010; 23: 542–50.

10. Cimbaljevic S, Suvakov S, Matic M, Pljesa-Ercegovac M, Pekmezovic T, Radić T, Coric V, Damjanovic T, Dimkovic N, Markovic R, Savic-Radojevic A, Simic T. Association of GSTO1 and GSTO2 polymorphism with risk of end-stage renal disease development and patient survival. J Med Biochem 2016; 35: 302–11.

11. Ritz E, Rychlik I, Locatelli F, Halimi S. End stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795–808.

12. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, Atkins RC. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol 2005; 14(7 Suppl 2): 131–8.

13. Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P, Van Lente F, Levey A. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2035–47.

14. Brück K, Stel V, Gambaro G, Hallan S, Völzke H, Ärnlöv J, et al. CKD Prevalence Varies across the European General Population. J Am Soc Nephrol 2016; 27: 2155–47.

15. Singh A, Farag Y, Mittal B, Karai Subramanian K, Reddy SRK, Acharya VN, et al. Epidemiology and risk factors of chronic kidney disease in India—results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrology 2013; 14: 114–23.

16. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009; 13: 621–30.

17. Barreto S, Ladeira R, Duncan B, Lopes A, Besenor I, et al. Chronic kidney disease among adult participants of the ELSA-Brasil cohort: association with race and socioeconomic position. J Epidemiol Community Health 2016; 70: 380–9.

18. Djukanović Lj, Ležačić V, Dimković N, Peruničić G, Bučković D, Bajičetić S, et al. Early detection of chronic kidney disease: Collaboration of Belgrade nephrologists and primary care physicians. Nefrologia (English Version) 2012; 32: 59–66.

19. Ponte B, Pruijm M, Marques-Vidal P, Pierre-Yves M, Burnier M, Paccaud F, et al. Determinants and burden of chronic kidney disease in the population–based CoLaus study: a cross-sectional analysis. Nephrol Dial Transplant 2013; 28: 3229–39.

20. Levey A, Stevens L, Schmid C, Zhang Y, Castro A, Feldman H, Kusek J, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–12.

21. Friedman AN. High protein diets: potential effects on the kidney in renal health and disease. Am J Kidney Dis 2004; 44: 950–62.

22. Chrysohoou C, Panagiotakos DB, Pitsavos C, Skoumas J, Zeimpekis A, Kastorini CM, et al. Adherence to the
Mediterranean diet is associated with renal function among healthy adults: the ATTICA study. J Ren Nutr 2010; 20: 176−84.

23. Unal B, Critchley JA, Capewell S. Modeling the decline in coronary heart disease death in England and Wales, 1981−2000: comparing contributions from primary and secondary prevention. BMJ 2005; 331: 614.

24. Delanaye P, Cavalier E, Cristol JP, Delanghe JR. Calibration and precision of serum creatinine and plasma cystatin C measurement: impact on the estimation of glomerular filtration rate. J Nephrol 2014; 27: 467−75.

25. Otero A, de Francisco ALM, Gayoso P, Garcia F, on behalf of the EPIRCE Study Group. Prevalence of chronic kidney disease in Spain: Results of the EPIRCE study. Nefrologia 2010; 30: 78−86.

26. Arora P, Vasa P, Brenner D, Iglar K, McFarlane Ph, Morrison H, et al. Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ 2013; 185: 417−23.

27. Fraser S, Aitken G, Taal M, Mindell J, Moon G, Day J, et al. Exploration of chronic kidney disease prevalence estimates using new measures of kidney function in the health survey in England. Plos One 2015; 10(2): e0118676.

28. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: Systematic review. BMC Pub Health 2008; 8: 117.

29. Zdrojewski L, Zdrojewski T, Rutkowski M, Bandosz P, Krol E, Wyrzykowski B, et al. Prevalence of chronic kidney disease in a representative sample of the Polish population: results of the NATPOL 2011 survey. Nephrol Dial Transplant 2016; 31: 435−9.

30. Navaneethan S, Schold J, Arrigain S, Kirwan J, Nally J. Body mass index and causes of death in chronic kidney disease. Kidney Int 2016; 89: 675−82.

31. Fujibayashi K, Fukuda H, Yokokawa H, Haniu T, Oka F, Ooike M, et al. Association between healthy lifestyle behaviors and proteinuria and the estimated glomerular filtration rate (eGFR). J Atheroscler Thromb 2012; 19: 932−40.

32. Pereira E, Pereira A, Andrade N, Nagbettini A, Pinto F, Batista S, et al. Prevalence of chronic renal disease in adults attended by the family health strategy. J Bras Nefrol 2016; 38: 22−30.

33. Marinković M, Illić N, Djokić D, Andrejević V, Damjanović G, Samardžić G, et al. Prevalence of hypertension in adults in the Šumadija District, Serbia – A cross-sectional study. Vojnosan Pregl 2014; 71: 245−50.

34. Zhang L, Wang F, Wang W, Liu B, Liu J, Chen M, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012; 379: 815−22.

35. Völzke H. Study of health in Pomerania (SHIP). Bundesgesundheitsbl 2012; 55: 790−4.

36. Sopić M, Jokić J, Spasojević-Kalimanovska V, Bogavac-Stanojević N, Simić-Ogrizović S, Kravljača M, Jelić Ivanović Z. Downregulation of adipor1 is associated with increased circulating adiponectin levels in serbian chronic kidney disease patients. J Med Biochem 2016; 35: 436–42.

37. Constantini L, Beanlands H, McCay E, Cattran D, Hladunewich M, Francis D. The self-management experience of people with mild to moderate chronic kidney disease. Nephrol Nurs J 2008; 35: 147−56.

38. Tout D, Plantinga L, Hsu CY, Jordan R, Burrows NR, Hedgeman E, et al. Chronic kidney disease awareness among individuals with clinical markers of kidney dysfunction. Clin J Am Soc Nephrol 2011; 6: 1838−44.